Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated calcium channel proteins are multi-subunit transmembrane ion channels that enable the selective influx of calcium ions in response to membrane depolarization[1][3][5]. The main structural component is the α₁ subunit, which forms both the ion-conducting pore and the voltage sensor; accessory subunits (α₂δ, β, γ) modulate the channel's expression, localization, and functional properties[1][3]. There are three primary VGCC subfamilies based on sequence and electrophysiological properties: - Cav1 (L-type channels): Activated by high voltage, resulting in large, long-lasting currents - Cav2 (N-, P/Q-, R-type channels): Also high-voltage-activated, with specific tissue distributions - Cav3 (T-type channels): Activated by low voltage and conduct transient currents[4][5] Calcium channels are essential for many physiological processes, including neurotransmitter release in neurons, contraction of muscle cells, hormone secretion, and activation of gene transcription[1][3][4]. Aberrant channel function contributes to several disease states such as hypertension, cardiac arrhythmias, neuropathic pain, and various neurological and oncological diseases[2][6]. Several therapeutic drugs target VGCCs, particularly for cardiovascular and neurological indications; these agents include dihydropyridines (such as amlodipine, nifedipine), phenylalkylamines (verapamil), benzothiazepines (diltiazem), and various experimental agents[2][5][6]. The principal mechanism of action is channel blockade, which reduces calcium influx and downstream signaling activity[2][5]. **Note on correctness:** "Calcium channel proteins" is a broad, somewhat ambiguous term that covers multiple distinct channel types, including not only voltage-gated calcium channels but also TRP channels, store-operated, mitochondrial, and calcium-activated channels[2]. For maximal specificity, use "Voltage-gated calcium channel protein" or, when possible, refer directly to the specific subunit or isoform (e.g., "Cav1.2 channel alpha-1C subunit") relevant to the physiological or pharmacological context.
Channel blockade (voltage-dependent calcium channel inhibition), Inhibition of calcium entry, Modulation of channel gating, Reduction of intracellular calcium signaling
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated calcium channel protein (VGCC).